Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Evidentiary Public Hearing, 30736-30738 [2018-14058]
Download as PDF
<![CDATA[
30736
Federal Register / Vol. 83, No. 126 / Friday, June 29, 2018 / Notices
ANNUAL BURDEN ESTIMATES
Instrument
Total/annual
number of
respondents
Number of
responses
per
respondent
Average
burden
hours per
response
Annual
burden
hours
Needs Assessment Survey .............................................................................
216
2
0.25
108
Estimated Total Annual Burden
Hours: 108.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Comments due within 60 days of
publication. In compliance with the
requirements of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
the Administration for Children and
Families is soliciting public comment
on the specific aspects of the
information collection described above.
DATES:
Copies of the proposed
collection of information can be
obtained and comments may be
forwarded by writing to the
Administration for Children and
Families, Office of Planning, Research,
and Evaluation, 330 C Street SW,
Washington, DC 20201, Attn: OPRE
Reports Clearance Officer. Email
address: OPREinfocollection@
acf.hhs.gov. All requests should be
identified by the title of the information
collection.
ADDRESSES:
The
Department specifically requests
comments on (a) whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
the quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Consideration will be given to
comments and suggestions submitted
within 60 days of this publication.
SUPPLEMENTARY INFORMATION:
Authority: Sec. 413, Pub. L. 115–31.
sradovich on DSK3GMQ082PROD with NOTICES
Mary B. Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2018–14037 Filed 6–28–18; 8:45 am]
BILLING CODE 4184–09–P
Food and Drug Administration
[Docket No. FDA–2014–N–2029]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Administrative
Practices and Procedures; Formal
Evidentiary Public Hearing
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
SUMMARY:
Fax written comments on the
collection of information by July 30,
2018.
DATES:
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, Fax: 202–
395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0191. Also
include the FDA docket number found
in brackets in the heading of this
document.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Amber Sanford, Office of Operations,
Food and Drug Administration, Three
White Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 301–796–8867, PRAStaff@
fda.hhs.gov.
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
17:58 Jun 28, 2018
Jkt 244001
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
Administrative Practices and
Procedures; Formal Evidentiary Public
Hearing
OMB Control Number 0910–0191—
Extension
The Administrative Procedures Act (5
U.S.C. 553(e)) provides that every
Agency shall give an interested person
the right to petition for issuance,
amendment, or repeal of a rule. Section
10.30 (21 CFR 10.30) sets forth the
format and procedures by which an
interested person may submit to FDA, in
accordance with § 10.20 (21 CFR 10.20),
a citizen petition requesting the
Commissioner of Food and Drugs (the
Commissioner) to issue, amend, or
revoke a regulation or order, or to take
or refrain from taking any other form of
administrative action.
The Commissioner may grant or deny
such a petition, in whole or in part, and
may grant such other relief or take other
action as the petition warrants.
Respondents are individuals or
households, State or local governments,
and not-for-profit institutions or groups.
Section 10.33 (21 CFR 10.33), issued
under section 701(a) of the Federal,
Food, Drug, and Cosmetic Act (FD&C
Act) (21 U.S.C. 371(a)), sets forth the
format and procedures by which an
interested person may request
reconsideration of part or all of a
decision of the Commissioner on a
petition submitted under 21 CFR 10.25
(Initiation of administrative
proceedings). A petition for
reconsideration must contain a full
statement in a well-organized format of
the factual and legal grounds upon
which the petition relies. The grounds
must demonstrate that relevant
information and views contained in the
administrative record were not
previously or not adequately considered
by the Commissioner. The respondent
must submit a petition no later than 30
days after the decision involved.
However, the Commissioner may, for
good cause, permit a petition to be filed
after 30 days. An interested person who
wishes to rely on information or views
not included in the administrative
record shall submit them with a new
petition to modify the decision. FDA
uses the information provided in the
request to determine whether to grant
E:\FR\FM\29JNN1.SGM
29JNN1
30737
Federal Register / Vol. 83, No. 126 / Friday, June 29, 2018 / Notices
the petition for reconsideration.
Respondents to this collection of
information are individuals of
households, State or local governments,
not-for-profit institutions, and
businesses or other for-profit
institutions who are requesting from the
Commissioner of FDA a reconsideration
of a matter.
Section 10.35 (21 CFR 10.35), issued
under section 701(a) of the FD&C Act,
sets forth the format and procedures by
which an interested person may request,
in accordance with § 10.20, the
Commissioner to stay the effective date
of any administrative action.
Such a petition must do the following:
(1) Identify the decision involved; (2)
state the action requested, including the
length of time for which a stay is
requested; and (3) include a statement of
the factual and legal grounds on which
the interested person relies in seeking
the stay. FDA uses the information
provided in the request to determine
whether to grant the petition for stay of
action.
Respondents to this information
collection are interested persons who
choose to file a petition for an
administrative stay of action.
Section 10.85 (21 CFR 10.85), issued
under section 701(a) of the FD&C Act,
sets forth the format and procedures by
which an interested person may request,
in accordance with § 10.20, an advisory
opinion from the Commissioner on a
matter of general applicability. When
making a request, the petitioner must
provide a concise statement of the
issues and questions on which an
opinion is requested, and a full
statement of the facts and legal points
relevant to the request. Respondents to
this collection of information are
interested persons seeking an advisory
opinion from the Commissioner.
FDA has developed a method for
electronic submission of citizen
petitions. The Agency still allows for
non-electronic submissions; however,
electronic submissions of a citizen
petition to a specific electronic docket
presents a simpler and more
straightforward approach. FDA has
created a single docket on https://
www.regulations.gov, the U.S.
Government’s consolidated docket
website for Federal Agencies, for the
initial electronic submission of all
citizen petitions. The advantage to this
is that it ensures efficiency and ease in
communication, quicker interaction
between citizen petitioners and FDA,
and easier access to FDA to seek input
through the citizen petition process.
The regulations in 21 CFR 12.22,
issued under section 701(e)(2) of the
FD&C Act, set forth the instructions for
filing objections and requests for a
hearing on a regulation or order under
§ 12.20(d) (21 CFR 12.20(d)). Objections
and requests must be submitted within
the time specified in § 12.20(e). Each
objection, for which a hearing has been
requested, must be separately numbered
and specify the provision of the
regulation or the proposed order. In
addition, each objection must include a
detailed description and analysis of the
factual information and any other
document, with some exceptions,
supporting the objection. Failure to
include this information constitutes a
waiver of the right to a hearing on that
objection. FDA uses the description and
analysis to determine whether a hearing
request is justified. The description and
analysis may be used only for the
purpose of determining whether a
hearing has been justified under 21 CFR
12.24 and does not limit the evidence
that may be presented if a hearing is
granted.
Respondents to this information
collection are those parties that may be
adversely affected by an order or
regulation.
Section 12.45 (21 CFR 12.45), issued
under section 701 of the FD&C Act, sets
forth the format and procedures for any
interested person to file a petition to
participate in a formal evidentiary
hearing, either personally or through a
representative. Section 12.45 requires
that any person filing a notice of
participation state their specific interest
in the proceedings, including the
specific issues of fact about which the
person desires to be heard. This section
also requires that the notice include a
statement that the person will present
testimony at the hearing and will
comply with specific requirements in 21
CFR 12.85, or, in the case of a hearing
before a Public Board of Inquiry,
concerning disclosure of data and
information by participants (21 CFR
13.25). In accordance with § 12.45(e) the
presiding officer may omit a
participant’s appearance.
The presiding officer and other
participants will use the collected
information in a hearing to identify
specific interests to be presented. This
preliminary information serves to
expedite the prehearing conference and
commits participation.
The respondents are individuals or
households, State or local governments,
not-for-profit institutions and
businesses, or other for-profit groups
and institutions.
In the Federal Register of February
22, 2018 (83 FR 7742), FDA published
a 60-day notice requesting public
comment on the proposed collection of
information. Although one comment
was received, it was not responsive to
the four collection of information topics
solicited and therefore will not be
discussed in this document.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
sradovich on DSK3GMQ082PROD with NOTICES
21 CFR section
10.30—Citizen petition .........................................................
10.33—Administrative reconsideration of action .................
10.35—Administrative stay of action ...................................
10.85—Requests for Advisory opinions ..............................
12.22—Filing objections and requests for a hearing on a
regulation or order ............................................................
12.45—Notice of participation ..............................................
Total ..............................................................................
1.There
Number of
responses per
respondent
Total annual
responses
Average
burden per
response
Total hours
220
6
6
4
1
1
1
1
220
6
5
4
24
10
10
16
5,280
60
50
64
5
5
........................
1
1
........................
5
5
........................
20
3
........................
100
15
5,569
are no capital costs or operating and maintenance costs associated with this collection of information.
The burden estimates for this
collection of information are based on
Agency records and experience over the
VerDate Sep<11>2014
17:58 Jun 28, 2018
Jkt 244001
past 3 years. The increase in burden
hours is due to an increase in the
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
number of respondents under several
provisions.
E:\FR\FM\29JNN1.SGM
29JNN1
30738
Federal Register / Vol. 83, No. 126 / Friday, June 29, 2018 / Notices
Dated: June 26, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018–14058 Filed 6–28–18; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–D–0268]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Labeling of Certain
Beers Subject to the Labeling
Jurisdiction of the Food and Drug
Administration
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on the information
collection provisions of the
recommended labeling of certain beers
subject to our labeling jurisdiction.
DATES: Submit either electronic or
written comments on the collection of
information by August 28, 2018.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before August 28,
2018. The https://www.regulations.gov
electronic filing system will accept
comments until midnight Eastern Time
at the end of August 28, 2018.
Comments received by mail/hand
delivery/courier (for written/paper
submissions) will be considered timely
if they are postmarked or the delivery
service acceptance receipt is on or
before that date.
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
VerDate Sep<11>2014
17:58 Jun 28, 2018
Jkt 244001
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2009–D–0268 for ‘‘Agency Information
Collection Activities; Proposed
Collection; Comment Request; Labeling
of Certain Beers Subject to the Labeling
Jurisdiction of the Food and Drug
Administration.’’ Received comments,
those filed in a timely manner (see
ADDRESSES), will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Domini Bean, Office of Operations,
Food and Drug Administration, Three
White Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 301–796–5733, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
E:\FR\FM\29JNN1.SGM
29JNN1
]]>Agencies
[Federal Register Volume 83, Number 126 (Friday, June 29, 2018)]
[Notices]
[Pages 30736-30738]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-14058]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2014-N-2029]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Administrative
Practices and Procedures; Formal Evidentiary Public Hearing
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by July
30, 2018.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
Fax: 202-395-7285, or emailed to [email protected]. All
comments should be identified with the OMB control number 0910-0191.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: Amber Sanford, Office of Operations,
Food and Drug Administration, Three White Flint North, 10A-12M, 11601
Landsdown St., North Bethesda, MD 20852, 301-796-8867,
[email protected].
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Administrative Practices and Procedures; Formal Evidentiary Public
Hearing
OMB Control Number 0910-0191--Extension
The Administrative Procedures Act (5 U.S.C. 553(e)) provides that
every Agency shall give an interested person the right to petition for
issuance, amendment, or repeal of a rule. Section 10.30 (21 CFR 10.30)
sets forth the format and procedures by which an interested person may
submit to FDA, in accordance with Sec. 10.20 (21 CFR 10.20), a citizen
petition requesting the Commissioner of Food and Drugs (the
Commissioner) to issue, amend, or revoke a regulation or order, or to
take or refrain from taking any other form of administrative action.
The Commissioner may grant or deny such a petition, in whole or in
part, and may grant such other relief or take other action as the
petition warrants. Respondents are individuals or households, State or
local governments, and not-for-profit institutions or groups.
Section 10.33 (21 CFR 10.33), issued under section 701(a) of the
Federal, Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 371(a)),
sets forth the format and procedures by which an interested person may
request reconsideration of part or all of a decision of the
Commissioner on a petition submitted under 21 CFR 10.25 (Initiation of
administrative proceedings). A petition for reconsideration must
contain a full statement in a well-organized format of the factual and
legal grounds upon which the petition relies. The grounds must
demonstrate that relevant information and views contained in the
administrative record were not previously or not adequately considered
by the Commissioner. The respondent must submit a petition no later
than 30 days after the decision involved. However, the Commissioner
may, for good cause, permit a petition to be filed after 30 days. An
interested person who wishes to rely on information or views not
included in the administrative record shall submit them with a new
petition to modify the decision. FDA uses the information provided in
the request to determine whether to grant
[[Page 30737]]
the petition for reconsideration. Respondents to this collection of
information are individuals of households, State or local governments,
not-for-profit institutions, and businesses or other for-profit
institutions who are requesting from the Commissioner of FDA a
reconsideration of a matter.
Section 10.35 (21 CFR 10.35), issued under section 701(a) of the
FD&C Act, sets forth the format and procedures by which an interested
person may request, in accordance with Sec. 10.20, the Commissioner to
stay the effective date of any administrative action.
Such a petition must do the following: (1) Identify the decision
involved; (2) state the action requested, including the length of time
for which a stay is requested; and (3) include a statement of the
factual and legal grounds on which the interested person relies in
seeking the stay. FDA uses the information provided in the request to
determine whether to grant the petition for stay of action.
Respondents to this information collection are interested persons
who choose to file a petition for an administrative stay of action.
Section 10.85 (21 CFR 10.85), issued under section 701(a) of the
FD&C Act, sets forth the format and procedures by which an interested
person may request, in accordance with Sec. 10.20, an advisory opinion
from the Commissioner on a matter of general applicability. When making
a request, the petitioner must provide a concise statement of the
issues and questions on which an opinion is requested, and a full
statement of the facts and legal points relevant to the request.
Respondents to this collection of information are interested persons
seeking an advisory opinion from the Commissioner.
FDA has developed a method for electronic submission of citizen
petitions. The Agency still allows for non-electronic submissions;
however, electronic submissions of a citizen petition to a specific
electronic docket presents a simpler and more straightforward approach.
FDA has created a single docket on https://www.regulations.gov, the
U.S. Government's consolidated docket website for Federal Agencies, for
the initial electronic submission of all citizen petitions. The
advantage to this is that it ensures efficiency and ease in
communication, quicker interaction between citizen petitioners and FDA,
and easier access to FDA to seek input through the citizen petition
process.
The regulations in 21 CFR 12.22, issued under section 701(e)(2) of
the FD&C Act, set forth the instructions for filing objections and
requests for a hearing on a regulation or order under Sec. 12.20(d)
(21 CFR 12.20(d)). Objections and requests must be submitted within the
time specified in Sec. 12.20(e). Each objection, for which a hearing
has been requested, must be separately numbered and specify the
provision of the regulation or the proposed order. In addition, each
objection must include a detailed description and analysis of the
factual information and any other document, with some exceptions,
supporting the objection. Failure to include this information
constitutes a waiver of the right to a hearing on that objection. FDA
uses the description and analysis to determine whether a hearing
request is justified. The description and analysis may be used only for
the purpose of determining whether a hearing has been justified under
21 CFR 12.24 and does not limit the evidence that may be presented if a
hearing is granted.
Respondents to this information collection are those parties that
may be adversely affected by an order or regulation.
Section 12.45 (21 CFR 12.45), issued under section 701 of the FD&C
Act, sets forth the format and procedures for any interested person to
file a petition to participate in a formal evidentiary hearing, either
personally or through a representative. Section 12.45 requires that any
person filing a notice of participation state their specific interest
in the proceedings, including the specific issues of fact about which
the person desires to be heard. This section also requires that the
notice include a statement that the person will present testimony at
the hearing and will comply with specific requirements in 21 CFR 12.85,
or, in the case of a hearing before a Public Board of Inquiry,
concerning disclosure of data and information by participants (21 CFR
13.25). In accordance with Sec. 12.45(e) the presiding officer may
omit a participant's appearance.
The presiding officer and other participants will use the collected
information in a hearing to identify specific interests to be
presented. This preliminary information serves to expedite the
prehearing conference and commits participation.
The respondents are individuals or households, State or local
governments, not-for-profit institutions and businesses, or other for-
profit groups and institutions.
In the Federal Register of February 22, 2018 (83 FR 7742), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. Although one comment was received, it was
not responsive to the four collection of information topics solicited
and therefore will not be discussed in this document.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of Average
21 CFR section Number of responses per Total annual burden per Total hours
respondents respondent responses response
----------------------------------------------------------------------------------------------------------------
10.30--Citizen petition......... 220 1 220 24 5,280
10.33--Administrative 6 1 6 10 60
reconsideration of action......
10.35--Administrative stay of 6 1 5 10 50
action.........................
10.85--Requests for Advisory 4 1 4 16 64
opinions.......................
12.22--Filing objections and 5 1 5 20 100
requests for a hearing on a
regulation or order............
12.45--Notice of participation.. 5 1 5 3 15
Total....................... .............. .............. .............. .............. 5,569
----------------------------------------------------------------------------------------------------------------
\1.\There are no capital costs or operating and maintenance costs associated with this collection of
information.
The burden estimates for this collection of information are based
on Agency records and experience over the past 3 years. The increase in
burden hours is due to an increase in the number of respondents under
several provisions.
[[Page 30738]]
Dated: June 26, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018-14058 Filed 6-28-18; 8:45 am]
BILLING CODE 4164-01-P
